Hotel-Dieu Quebec recognized for 1000th permanent prostate implant treatment; 200 patients treated with Nucletron’s FIRST™ System

February 14 2006  

Veenendaal, The Netherlands,–  Hotel-Dieu Quebec, The University Hospital Center of Quebec (CHUQ) have furthered the development and adoption of Image Guided Brachytherapy methods for the treatment of Prostate Cancer utilizing Nucletron’s FIRST System for permanent prostate seed implants.


With Nucletron’s FIRST system, the clinician can see for the first time the effect of the seed implant procedure, and make adjustments where necessary in the plan. Optimized treatment can be delivered immediately, making the planning and treatment one single, integrated and high quality procedure.


“We congratulate CHUQ on the significant accomplishment of eliminating patient delay for prostate implants and on the occasion of treating their 1000^th prostate brachytherapy patient,” stated Jeroen Cammeraat, President of Nucletron Corporation.  “Over 200 patients were recently treated with Nucletron’s Fully Integrated Real-time Seed Treatment (FIRST) System. Collaboration between CHUQ and Nucletron has led to the adoption of clinical techniques that utilize FIRST to improve the planning and delivery of permanent seed implants,” Mr. Cammeraat added.


Cancer treatment is in constant evolution and the practice of prostate implants is not an exception. Since Dr. Jean Roy established prostate implants at CHUQ, the technique has continued to evolve. Now, Drs Éric Vigneault and André-Guy Martin have continued to improve the technique from manual source delivery to automated delivery; and from manual dosimetry planning to inverse planning. They have inspired others to establish this practice in other regions.


Nucletron’s FIRST System is comprised of SPOT PRO™, the unique mobile 3D planning system, which offers live-planning with 3D needle guidance and real-time dosimetry updates. Ideal for the treatment planning of permanent seed implants, seedSelectron^® automatically delivers the seeds to match this ‘live-plan' – without delay and without extra radiation exposure.



About CHUQ

The University Hospital Center of Quebec (CHUQ) is an establishment that offers general and specialized care to the clientele of the Quebec City region and the eastern region of the Province of Quebec.  It aims to attain a standard of the highest quality and excellence regarding the care and organization of medical services to the population. 


The CHUQ, in partnership with the University of Laval, favours the development of innovative approaches aimed at the improvement of the population’s health.  It is also a leader in teaching, research and evaluation of new medical technologies. Hotel Dieu Quebec was originally chartered by Louis XIII in 1639, making it the oldest hospital in all of North America.



About Nucletron B.V.

Nucletron is a global leader in the development, manufacture, sales, service and support of the world’s most innovative products for cancer treatment, with particular expertise in treatment planning systems, brachytherapy, simulation, integrated software solutions for oncology, and comprehensive support and professional education and services. The company has over 20 offices worldwide, including its corporate headquarters in Veenendaal, the Netherlands. For more information on Nucletron, please visit: https://www.nucletron.com/.


Nucletron B.V. is a subsidiary of Delft Instruments. Delft Instruments is the holding company of an international group of companies, which hold a leading position in their respective markets with high quality, high technology products and services. Delft Instruments is active through wholly owned subsidiaries in more than 30 countries worldwide, employs approximately 1,000 people and reported turnover of EUR 261.6 million in 2004. For more information on Delft Instruments, please visit: http://www.delftinstruments.com/.



For further information: